

**Supplementary Material for:**

**Intravenous Edaravone Treatment in ALS Is Associated With Improved Survival: Results From an Administrative Claims Analysis**

**Brooks BR, et al.**

**Contents**

**Supplementary Table.** Demographic and clinical characteristics of patient population (before matching).....2

**Supplementary Figure.** Standard mean difference of variables between IV edaravone-treated ALS patients and non-IV edaravone-treated ALS patients before and after matching.....4

**Supplementary Table.** Demographic and clinical characteristics of patient population (before matching).


Characteristics	IV Edaravone Treatment		p value
	Yes	No	
N	320	12,572	
Region, no. (%)			0.096
Midwest	86 (26.9)	2866 (22.8)	
Northeast	59 (18.4)	1919 (15.3)	
South	102 (31.9)	4828 (38.4)	
West	72 (22.5)	2914 (23.2)	
Unknown	1 (0.3)	45 (0.4)	
Age group, y, no. (%)			<0.001
18–39	5 (1.6)	516 (4.1)	
40–49	32 (10.0)	1062 (8.4)	
50–59	78 (24.4)	2263 (18.0)	
60–69	113 (35.3)	3649 (29.0)	
70–79	85 (26.6)	3447 (27.4)	
80+	7 (2.2)	1635 (13.0)	
Age, mean (SD)	62.7 (10.2)	65.1 (13.1)	0.001
Sex, no. (%)			0.898
Female	135 (42.2)	5434 (43.2)	
Male	185 (57.8)	7135 (56.8)	
Unknown	0 (0.0)	3 (0.0)	
Race, no. (%)			0.428
White	238 (74.4)	9040 (71.9)	
Other	51 (15.9)	2365 (18.8)	
Unknown	31 (9.7)	1167 (9.3)	
Payor, no. (%)			
Commercial	131 (40.9)	4709 (37.5)	0.226
Medicare Advantage	189 (59.1)	7863 (62.5)	
Pre-index disease duration,* days, median (IQR)	97.5 (46.8, 251.2)	1132.0 (15.0, 2540.0)	<0.001
Pre-index claims for cardiovascular disease, no. (%)	30 (.4)	743 (5.9)	0.014
History of riluzole prescription, no. (%)	209 (65.3)	2359 (18.8)	<0.001

Pre-index claim for gastrostomy tube placement, no. (%)	25 (7·8)	1893 (15·1)	<0·001
Pre-index claim for artificial nutrition, no. (%)	39 (12·2)	2504 (19·9)	0·001
Pre-index claim for noninvasive ventilation, no. (%)	54 (16·9)	2441 (19·4)	0·287
Pre-index claims for all-cause hospitalization, no. (%)	73 (22·8)	5649 (44·9)	<0·001

\*Defined as the period between the date for first claim for ALS diagnosis and the first claim of IV edaravone for IV edaravone-treated patients or the date IV edaravone was available on the market (8 August 2017) for patients with no IV edaravone treatment.

ALS, amyotrophic lateral sclerosis. IV, intravenous. Y, year.

**Supplementary Figure.** Standard mean difference of variables between IV edaravone-treated ALS patients and non-IV edaravone-treated ALS patients before and after matching.



ALS, amyotrophic lateral sclerosis. IV, intravenous.